Skip to main content

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Aroa Soriano Fernández

Institutions of which they are part

Main researcher
Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca

Projects

Investigació translacional en càncer infantil (GRE)

IP: Josep Sánchez de Toledo Codina
Collaborators: Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Anna Llort Sales, Raquel Hladun Alvaro, Investigació translacional en càncer infantil (GRE) , Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 30000
Reference: 2014 SGR 660
Duration: 01/01/2014 - 31/12/2016

Nanoterapia basada en microRNAs: nuevo tratamiento para tumores pediátricos del sistema nervioso

IP: Miguel Segura Ginard
Collaborators: Luís Gros Subias, Aroa Soriano Fernández, Josep Sánchez de Toledo Codina, Constantino Sábado Álvarez
Funding agency: Instituto de Salud Carlos III
Funding: 116765
Reference: PI14/00561
Duration: 01/01/2015 - 31/12/2017

TERAPIA PERSONALIZADA CONTRA ERK5 EN NEUROBLASTOMA

IP: Aroa Soriano Fernández
Collaborators: Miguel Segura Ginard
Funding agency: Asociación Española Contra el Cáncer
Funding: 20000
Reference: 2014/AECC-JB/SORIANO
Duration: 31/01/2015 - 31/01/2017

Red Temática de Investigación Cooperativa en Cáncer - RTICC

IP: Josep Sánchez de Toledo Codina
Collaborators: Luís Gros Subias, Pablo Velasco Puyó, Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Constantino Sábado Álvarez, Anna Llort Sales, Laura Alonso Garcia, Josep Roma Castanyer
Funding agency: Instituto de Salud Carlos III
Funding: 186750
Reference: RD12/0036/0016
Duration: 01/01/2013 - 30/06/2017

Related news

The meeting was an opportunity to get to know projects from both institutions and to promote interaction between professionals.

A study jointly led by the Hospital Clínic of Barcelona and the Vall d'Hebron Research Institute (VHIR) confirms the effectiveness of neonatal screening in reducing morbidity among children with sickle cell disease (SCD).

Active participation by patients and families in studies helps identify more effective therapies that improve quality of life and survival.

Related professionals

Génesis Martín Fernández

Génesis Martín Fernández

Research technician
Read more
Anna Maria Cueto Gonzalez

Anna Maria Cueto Gonzalez

Main researcher
Genetics Medicine
Read more
Thaïs Murciano Carrillo

Thaïs Murciano Carrillo

Childhood Cancer and Blood Disorders
Read more
Pilar Bonet Palomares

Pilar Bonet Palomares

Research technician
Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT)
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.